| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Biomerica, Inc.$1.49
-0.1 (-6.28%)
F 5Pipeline Score MedTech · Clinical
Market Cap
7.69 M
EPS
-1.50
P/E Ratio
-
Value Trade
21.27 K
SEC Financials
Q1 2026Dilution Risk
Revenue
987.00 K
R&D Expenses
178.00 K
Total Assets
4.88 M
Total Liabilities
1.56 M
Equity
3.32 M
D/E Ratio
12,345
2.89 %
Week
15.81 %
1 Month
12.67 %
3 Month
9.69 %
6 Month
-91.52 %
5 Year
-94.44 %
All Time
Cash Data
Cash Position
1.50 M
Monthly Burn
433.00 K
Runway
0 mo
Burn Trend
StableSEC Filing
Apr 13, 2026
Overview
Volume
11.50 K
52 Week Range
1.87 - 4.60
% held by Insiders
14.16 %
% held by Institutions
3.62 %
Enterprise Value
6.55 M
Total Shares
3.09 M
Short %
0.86 %
Float Shares
2.56 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F5
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 868 of 913)
Percentile RankBiomerica, Inc. has significant pipeline risk (5/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
inFoods IBS test | Irritable Bowel Syndrome (IBS) | — | 2025-06-05 | treatment group responder: 59.6%; control group responder: 42.2%; IBS C treatment group: 67.1%; IBS C control group: 35.8%; IBS M treatment group: 66.0%; IBS M control group: 29.5% Read More | Biomerica’s inFoods IBS Clinical Study Results Published in June Issue of Gastroenterology Read More | |
inFoods IBS test | Irritable Bowel Syndrome (IBS) | — | 2025-06-05 | treatment group responder: 59.6%; control group responder: 42.2%; IBS C treatment group: 67.1%; IBS C control group: 35.8%; IBS M treatment group: 66.0%; IBS M control group: 29.5% Read More | Biomerica’s inFoods IBS Clinical Study Results Published in June Issue of Gastroenterology Read More | |
inFoods IBS test | Irritable Bowel Syndrome (IBS) | — | 2025-06-05 | treatment group responder: 59.6%; control group responder: 42.2%; IBS C treatment group: 67.1%; IBS C control group: 35.8%; IBS M treatment group: 66.0%; IBS M control group: 29.5% Read More | Biomerica’s inFoods IBS Clinical Study Results Published in June Issue of Gastroenterology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BMRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BMRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BMRABiomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica, Inc. has entered a Master Services Agreement worth $1.75 million with a confidential life sciences company for the development of IVD assays. The agreement will be executed over multiple Statements of Work and is set for an initial three-year term. This engagement allows Biomerica to utilize its established expertise in assay development while maintaining its focus on its primary product, inFoods® IBS.
Read more →BMRABiomerica’s inFoods IBS Data Accepted for Presentation at Digestive Disease Week 2026
Biomerica, Inc. announced that their inFoods IBS diagnostic-guided therapy has been accepted for presentation at the upcoming Digestive Disease Week 2026. This event, being the largest in gastroenterology, showcases the increasing interest in non-pharmacologic dietary management for irritable bowel syndrome (IBS). The study, conducted by leading institutions, builds on prior promising trial results indicating significant symptom relief for patients who eliminated identified food triggers. The acceptance of this presentation marks a significant recognition of inFoods IBS's potential in addressing IBS treatment needs.
Read more →BMRABiomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Biomerica has received confirmation from the Medicare Administrative Contractor that claims for its inFoods® IBS test will be reviewed on an individual basis, paving the way for Medicare coverage. The test, which identifies food triggers for IBS, is supported by strong clinical evidence and has a pre-established payment rate of $300. This development is expected to facilitate revenue generation for Biomerica starting January 1, 2026.
Read more →BMRABiomerica Launches inFoods IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
Biomerica, Inc. has launched its inFoods® IBS platform in Canada, marking the company's first commercial foray into this market. The launch is facilitated through partnerships with Phoenix Airmid Biomedical for distribution and CanAlt Health Labs for laboratory services. With an estimated 5 million Canadians affected by IBS, the inFoods® platform aims to meet the substantial and underserved demand for non-pharmaceutical treatment options. Clinical data supporting the product highlights its potential effectiveness in addressing gastrointestinal symptoms.
Read more →BMRABiomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its third quarter fiscal 2026 financial results, highlighting positive real-world data for its inFoods®IBS product, which showed significant pain and bloating reduction in IBS patients. The company also announced a national Medicare payment rate for inFoods®IBS, enhancing patient access. Despite a decrease in net sales and an increase in net loss, European revenue grew by 45%, reflecting strong market demand.
Read more →BMRABiomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
Biomerica has achieved a significant milestone by receiving its first commercial order for its Hp Detect™ test from one of the largest clinical laboratory chains in Europe. The order is particularly important as it positions Biomerica for potential broader adoption of its diagnostic products within the European market, especially given the high prevalence of H. pylori infections. The company expects this initial order to lead to additional recurring orders as its product becomes part of the customer's routine testing protocol. The announcement underscores the growing commercial viability of Biomerica's diagnostic products amidst rising public health concerns related to H. pylori.
Read more →BMRABiomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Biomerica has received MHRA registration for its hp+detect™ diagnostic test, enabling commercial sales in Great Britain. This test detects H. pylori, a significant health concern linked to gastric cancer. The company is actively pursuing partnerships in the UK market to enhance access to this diagnostic tool. The registration marks a significant milestone for Biomerica's international expansion.
Read more →BMRA▼ -5.1%on this news
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Biomerica, Inc. reported positive results from its real-world study of inFoods® IBS, showing that nearly 60% of patients experienced clinically meaningful reductions in abdominal pain and 68% achieved improvement in bloating. The study involved 69 patients and utilized FDA-recognized responder definitions, reinforcing the product's clinical utility. These findings are consistent with previous controlled trials, enhancing confidence in inFoods® IBS's effectiveness.
Read more →BMRAVietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease screening test. This at-home test aims to improve early detection of colorectal cancer, addressing a significant public health issue in Vietnam, where the survival rate for colorectal cancer is notably low. The company plans to collaborate with a major distributor to ensure widespread availability across various sales channels.
Read more →BMRABiomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica reported its financial results for the second quarter of fiscal 2026, showing a decrease in net sales to $1.21 million compared to $1.64 million in the prior year. The company is transitioning to higher-margin diagnostic products, which has led to a strategic pivot affecting current revenues. Despite a net loss of $1.32 million, management remains optimistic about future growth driven by new product launches and partnerships.
Read more →BMRABiomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
Biomerica has announced that the Centers for Medicare & Medicaid Services (CMS) set a national Medicare payment rate of $300 for its inFoods IBS test, effective January 1, 2026. This decision follows the approval of a unique CPT code for the test, enhancing patient access and commercial growth potential. The inFoods IBS test aims to address the unmet needs of IBS patients by identifying food triggers and providing targeted dietary recommendations.
Read more →BMRAEgyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid screening tests. This includes tests for colorectal, breast, and prostate cancers, as well as chronic diseases like kidney disease and H. pylori infection. The tests aim to facilitate early detection and are designed for easy use in various settings, addressing significant health needs in Egypt.
Read more →BMRABiomerica’s inFoods IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica, Inc. has announced that its inFoods IBS diagnostic-guided therapy product is featured in the Fall 2025 issue of Biotherapeutics Quarterly. The article highlights results from a large clinical trial indicating that the inFoods assay effectively identifies dietary triggers for IBS, leading to significant symptom relief. The study demonstrated a higher percentage of pain reduction in patients following the inFoods-guided diet compared to a placebo group, showcasing a promising direction for precision medicine in managing IBS. The innovative approach aims to enhance patient experience by minimizing unnecessary dietary restrictions.
Read more →BMRABiomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Biomerica, Inc. has announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to cater to increasing market demand. The company aims to enhance its capabilities, providing comprehensive support from concept to commercial manufacturing. With over 40 years of experience, Biomerica is well-positioned to assist diagnostic innovators while its updated website aims to improve partner engagement.
Read more →BMRA▲ +5.2%on this news
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
Biomerica, Inc. has entered a marketing services agreement with Henry Schein, Inc. to promote its inFoods® IBS test across the U.S., excluding New York. This partnership aims to enhance the adoption of a non-drug therapy for IBS, leveraging Henry Schein's extensive distribution network. A recent clinical study published in Gastroenterology supports the test's efficacy, particularly for IBS-M patients.
Read more →BMRABiomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its financial results for the first quarter of fiscal 2026, revealing net sales of $1.4 million, a decrease from $1.8 million in the prior year. Despite lower sales, the company saw an increase in gross profit due to a favorable product mix. Operating expenses also decreased, leading to an improved operating loss of $1.1 million. Notably, Biomerica achieved a net profit of approximately $2,000, contrasting with a net loss of $1.3 million in the same quarter last year.
Read more →BMRAGary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Inc. has appointed Gary Huff, former CEO of LabCorp Diagnostics, to its Board of Directors. Huff's extensive experience in the diagnostics industry is expected to contribute to Biomerica's growth and innovation, particularly with its inFoods® IBS product aimed at improving patient care for irritable bowel syndrome. His strategic vision is anticipated to drive sustainable growth for the company.
Read more →BMRANEWS - For Immediate Release Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors - Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy and sales gr
Biomerica Inc. has appointed Gary Huff, former CEO of LabCorp Diagnostics, to its Board of Directors. Huff brings decades of experience in the diagnostics and healthcare services industry, with a successful history in managing various laboratory enterprises. He aims to contribute to Biomerica's growth, particularly in advancing the inFoods IBS product which targets dietary management for irritable bowel syndrome. This appointment is expected to bolster the company's innovative diagnostic portfolio.
Read more →BMRABiomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
Biomerica has launched the inFoods® IBS Trigger Food Navigator, an AI-driven tool designed to enhance dietary compliance for patients with Irritable Bowel Syndrome (IBS). This tool identifies specific food triggers and offers personalized meal suggestions, making it easier for patients to adhere to their dietary plans. Clinical studies have shown significant symptom relief, improving the quality of life for IBS patients.
Read more →BMRAUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use
Biomerica, Inc. announced that the UAE Ministry of Health has approved its Fortel® Kidney Test for home use. This rapid test allows for the early detection of kidney damage, particularly beneficial for individuals with diabetes and hypertension. The approval aims to enhance healthcare access in the UAE, where these conditions are prevalent, and positions Biomerica as a leader in preventive diagnostics.
Read more →BMRABiomerica Reports Fiscal 2025 Year End Results
Biomerica, Inc. reported its fiscal 2025 results, showing a 19% improvement in operating loss despite a slight decrease in net sales from $5.4 million to $5.3 million. The company's operating expenses were significantly reduced, resulting in notable efficiencies and cash savings. Strategic growth initiatives, including advancements in the inFoods® IBS test, contributed positively to the overall performance. However, revenue decline reflects ongoing economic challenges and shifts in product demand.
Read more →BMRA▲ +15.8%on this news
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
Biomerica, Inc. has received approval from the UAE Ministry of Health for its Fortel® Ulcer Test, allowing for home use. This rapid diagnostic test detects H. pylori, a major cause of gastric diseases. With approximately 41% of the UAE population affected, the test aims to facilitate early detection and treatment, potentially reducing serious complications associated with the infection.
Read more →BMRAInFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
Biomerica, Inc. announced that the American Medical Association has issued a CPT code for its inFoods IBS test, effective October 1, 2025. This code will facilitate insurance claims and enhance patient access to the test, which identifies food triggers for IBS symptoms. The test has shown significant clinical effectiveness in trials, supporting its commercialization strategy.
Read more →BMRAClinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica Inc. has appointed Scott Madel as Chief Commercial Officer to enhance the commercialization of its inFoods®IBS product. With extensive experience in healthcare and diagnostics, Madel aims to drive revenue growth and expand strategic partnerships. The inFoods®IBS test is designed to identify food triggers for IBS symptoms, offering a precision-based approach to treatment.
Read more →BMRANEWS - For Immediate Release Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair - Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations - Mr
Biomerica has appointed Eric B. Chin to its Board of Directors, effective June 4, 2025. He will serve as Chairperson of the Audit Committee and participate in the Nominating and Corporate Governance Committee as well as the Compensation Committee. With over 20 years of experience in public and private healthcare organizations, Chin's appointment is expected to bolster Biomerica's financial oversight and governance as the company expands its commercialization efforts. He replaces Cathy Coste, who resigned without any disagreements related to company operations or policies.
Read more →BMRABiomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Biomerica, Inc. announced the appointment of Eric B. Chin to its Board of Directors and as Chairperson of the Audit Committee, effective June 4, 2025. Chin, who has over 20 years of financial experience, currently serves as CFO of Akido Labs and has a distinguished background within the healthcare sector. His addition is expected to bolster Biomerica's corporate governance and financial oversight as the company seeks to expand its commercialization efforts. Chin replaces Cathy Coste, whose departure was not due to any disagreement with the company.
Read more →BMRABiomerica’s inFoods IBS Clinical Study Results Published in June Issue of Gastroenterology
Biomerica, Inc. announced the publication of a pivotal clinical trial on its inFoods IBS test in the June 2025 issue of Gastroenterology. The study, conducted across eight U.S. academic centers, demonstrated statistically significant symptom improvement in Irritable Bowel Syndrome (IBS) patients using a personalized elimination diet based on the test's findings. Notably, results indicated that the therapy might particularly benefit IBS-M patients, who currently lack FDA-approved drug treatments. This publication marks a significant advancement in dietary management strategies for IBS and reinforces the efficacy of the inFoods IBS test.
Read more →BMRABiomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods IBS using a First of Its Kind Real-Time IBS Patient Feedback System
Biomerica, Inc. announced promising real-world results for its inFoods IBS product, revealing a significant reduction in gastrointestinal symptoms among over 360 patients. The study indicated an average 48.5% decrease in GI pain and a 49.8% decrease in bloating over an eight-week period. Additionally, the launch of a proprietary real-time patient feedback system aims to improve treatment personalization and outcomes. These findings further validate earlier clinical trial results, underscoring a growing interest in innovative, non-drug therapies for managing Irritable Bowel Syndrome (IBS).
Read more →BMRA▼ -26.3%on this news
Biomerica Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on
Biomerica, Inc. (NASDAQ: BMRA) has announced a 1-for-8 reverse stock split of its common shares effective April 21, 2025, to help meet Nasdaq's minimum bid price requirements. Approximately 20 million shares will be consolidated into approximately 2.5 million shares following the split. Shareholders authorized the stock split at the 2024 Annual Meeting. Biomerica aims to boost its stock price to maintain its listing on the Nasdaq Capital Market.
Read more →BMRA▼ -26.3%on this news
Biomerica Announces Reverse Stock Split
Biomerica, Inc. has announced a 1-for-8 reverse stock split effective April 21, 2025, as part of its strategy to meet Nasdaq's minimum bid price requirements. This split will reduce the number of shares outstanding from approximately 20 million to about 2.5 million shares. Stockholders had approved this action at the 2024 Annual Meeting, reflecting their support for the company's efforts to stabilize its share price in the market. The company continues focusing on its biomedical technologies despite the necessity for this adjustment.
Read more →BMRABiomerica Reports Third Quarter Fiscal 2025 Financial Results
Biomerica, Inc. reported its third quarter financial results for fiscal 2025, highlighting a 10% year-over-year increase in revenue and improved gross margins. The company achieved significant cost savings ahead of schedule, reducing cash burn by more than 55%. Key developments included the regulatory approval of the Fortel® PSA Screening Test and successful clinical results from the inFoods® IBS test, which contributed to improved patient outcomes. Overall, Biomerica's strategic focus on operational efficiencies has strengthened its financial position.
Read more →BMRA▲ +9.4%on this news
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis
Biomerica has successfully obtained IVDR certification for its food intolerance products aimed at managing Crohn's Disease and Ulcerative Colitis. This certification allows sales in the European Union and underscores the company's commitment to high-quality diagnostics. The approval reflects Biomerica's innovative approach to addressing dietary triggers in these chronic conditions. With the growing market for treatments in this area, Biomerica is well positioned for expansion within Europe and potentially other international markets.
Read more →BMRA▼ -8.5%on this news· ran to -27% by day 3
Biomerica’s inFoods IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
Biomerica has announced positive results from its inFoods IBS clinical trial, published in the journal Gastroenterology. Patients following a personalized dietary therapy based on the inFoods IBS blood test experienced significant relief from abdominal pain compared to a control group. The trial involved 238 IBS patients, demonstrating the efficacy of the inFoods IBS test in identifying food triggers that exacerbate symptoms. This research supports a precision nutrition approach for IBS management, especially for subtypes like IBS-C and IBS-M where traditional treatments are lacking.
Read more →BMRA▲ +6.8%on this news· ran to +116% by day 1
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
Biomerica, Inc. reported its second quarter fiscal 2025 financial results, showing a 5% increase in revenue year-over-year, reaching $1.64 million. The company achieved improved gross margins of 27% and implemented significant cost-saving measures, reducing operating expenses by 26%. Additionally, Biomerica launched the inFoods IBS test for direct-to-consumer orders, while securing three crucial patents addressing digestive health conditions. The financial results illustrate the company's commitment to aligning operations with strategic priorities and pursuing further growth opportunities.
Read more →BMRABiomerica Secures Three Key International Patents for inFoods Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
Biomerica has received three notices of allowance for patents covering its inFoods technology, aimed at treating GERD, Crohn’s disease, and ulcerative colitis across multiple European countries. This strategic move enhances the company's position in multi-billion-dollar markets, offering a personalized approach to treatment that addresses underlying food triggers for these gastrointestinal conditions. The recently issued patents signify a milestone in Biomerica's mission to innovate patient care while potentially reducing the healthcare burden associated with these diseases.
Read more →BMRA▲ +18.7%on this news
Biomerica Announces Direct-to-Consumer Availability of inFoods IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
Biomerica, Inc. has launched the inFoods® IBS test, which allows patients to order the test directly at home for managing Irritable Bowel Syndrome (IBS) symptoms like bloating and gastrointestinal pain. The test uses a finger-prick blood sample to identify specific food triggers, enabling tailored dietary changes to alleviate symptoms effectively. A recent clinical study has shown significant improvements in symptom relief compared to traditional treatments, supporting the test's promise as a non-invasive management option for IBS. The service includes remote physician oversight, combining convenience with professional medical guidance.
Read more →BMRA▲ +9%on this news
Biomerica Reports First Quarter Fiscal 2025 Financial Results
Biomerica, Inc. reported its first quarter fiscal 2025 financial results, showing a 6% increase in total revenue to $1.8 million compared to the same period last year. The company received Saudi FDA approval for its At-Home PSA Screening Test, enhancing early detection of prostate cancer. Cost-saving measures have been implemented, expected to reduce annual expenses by up to 23%. However, the company saw an increase in operating and net losses, partially attributable to one-time costs related to a reduction-in-force aimed at operational efficiency.
Read more →BMRABiomerica Reports Fiscal 2024 Year End Results
Biomerica, Inc. reported its fiscal year 2024 financial results, highlighting a slight revenue increase to $5.4 million driven mainly by its EZ Detect™ and Aware® products. A significant cost savings plan has been implemented to reduce expenses by $1.0 to $1.4 million, which follows a reported net loss of $6.0 million for the year, an improvement from the previous year. The company's inFoods® IBS pilot program is progressing ahead of schedule, showcasing their growth strategy in the gastrointestinal diagnostics market.
Read more →BMRABiomerica Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers
Biomerica, Inc. has announced a significant enhancement to its inFoods IBS system, allowing patients to self-collect blood samples at home using a finger-stick device. This innovation aims to simplify the patient's experience and improve access for millions of individuals suffering from Irritable Bowel Syndrome (IBS). The test uniquely identifies specific foods that trigger IBS symptoms and is supported by clinical studies showing substantial pain reduction. The company is optimistic that this development will broaden its market reach and potentially increase its revenues significantly.
Read more →BMRABiomerica Announces inFoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
Biomerica, Inc. (NASDAQ: BMRA) has announced the initiation of a pilot program for its inFoods IBS product with a prominent group of 1,100 physicians set to launch in June 2024. This innovative product aims to identify dietary triggers specific to IBS patients, potentially revolutionizing the management of the condition. Extensive clinical research supports its efficacy, showing significant symptom relief compared to placebo in studies conducted at prestigious medical institutions. Positive clinical data will be presented at the Digestive Disease Week 2024 Conference, highlighting its potential impact on IBS treatment.
Read more →BMRA▼ -20%on this news
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Biomerica has established a multi-year exclusive distribution agreement with a leading healthcare conglomerate in the UAE to enhance colorectal and breast cancer screening. The deal introduces Biomerica’s EZ Detect™ at-home colon cancer screening test and the Aware® breast examination device to the UAE market, promoting early detection. The partnership aims to integrate these tests into national health protocols, improving accessibility and efficiency in cancer screening initiatives within the region.
Read more →BMRA▼ -7%on this news
Biomerica provides update on inFoods IBS expansion
Biomerica, Inc. announced the expansion of its inFoods IBS product into new regions and among new physician groups, resulting in a significant increase in adoption. The company has also secured five new patents, bringing its total to 25, enhancing its intellectual property portfolio. Discussions are ongoing for the product's launch with large non-GI physician groups, indicating potential growth in new patient populations. Clinical studies have demonstrated the product's ability to significantly improve symptoms for IBS patients.
Read more →BMRABiomerica Reports Third Quarter 2024 Financial Results
Biomerica, Inc. reported its third quarter financial results for fiscal 2024, revealing a reduction in loss per share from $0.40 to $0.27. Despite a slight decrease in net sales, the company is optimistic about growth prospects, particularly for its inFoods IBS test, which will showcase positive clinical data at the upcoming Digestive Disease Week conference. The company is also expanding its sales force and actively marketing its new HP Detect test, which has been cleared by the FDA. However, challenges remain in terms of rising operating expenses and declining cash reserves.
Read more →BMRA▼ -6.5%on this news
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Biomerica has announced that data regarding its InFoods IBS technology will be presented at the 2024 Digestive Disease Week conference. This presentation will highlight clinical evidence supporting the use of InFoods in alleviating symptoms for IBS patients. The results indicate significant improvements in abdominal pain for patients using the treatment as opposed to a placebo. The conference will take place from May 18 to 24, 2024, in Washington, D.C.
Read more →BMRABiomerica Reports Second Quarter 2024 Financial Results
Biomerica, Inc. reported its financial results for the second quarter of fiscal 2024, showing a revenue increase of 10.3% excluding Covid test sales. The company has narrowed its loss per share to $0.09 as a result of disciplined expense management. Notably, Biomerica received US FDA 510(k) clearance for its Hp Detect™ ELISA test aimed at detecting H. pylori, which affects a significant portion of the population. However, the company continues to experience an operating loss and a decline in cash reserves compared to the previous year.
Read more →BMRA▲ +66.7%on this news
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
Biomerica, Inc. has received FDA 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test, which is designed to identify the H. pylori bacteria infecting about 35% of the U.S. population. The test will aid in diagnosing H. pylori infections and assessing treatment results. This development is significant given the association of H. pylori with gastric cancer, which is the third leading cause of cancer-related death globally. The company anticipates a positive impact on healthcare by providing an efficient and accurate diagnostic tool for clinicians.
Read more →BMRABiomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
Biomerica, Inc. has announced its participation in the 14th Annual Craig-Hallum Alpha Select Conference scheduled for November 16, 2023. The conference will take place at the Sheraton New York Times Square Hotel, where CEO Zackary Irani will host various meetings. This engagement underscores Biomerica's commitment to advancing its biomedical technology and enhancing stakeholder relations. The company specializes in diagnostic and therapeutic products, particularly in the gastrointestinal and inflammatory disease sectors.
Read more →BMRA▲ +11.1%on this newsshared move
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
Biomerica, Inc. announced the expansion of its inFoods IBS product with several new GI groups adopting the therapy. This is part of the company's national rollout plan for 2024, which is expected to drive significant revenue growth. Notably, the inFoods IBS product has demonstrated positive clinical outcomes in studies conducted at prestigious medical centers, providing a promising alternative in IBS management. The company's recent hires in sales management are aimed at enhancing distribution and integration of the product into clinical workflows.
Read more →BMRABiomerica Reports First Quarter 2024 Financial Results
Biomerica, Inc. reported its financial results for the first quarter of fiscal 2024, showing a 16.3% increase in revenues excluding Covid test sales. The company expects to achieve profitability supported by its current cash position and a robust corporate strategy. Improvements in financial performance were noted, including a significant enhancement in gross margin, which rose from -3.4% to 24.1%. The pre-launch phase of the inFoods IBS product has been completed, with a national market launch anticipated in 2024.
Read more →BMRANEWS- For Immediate Release Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors - Kenny has a proven track record of driving growth at companies within the healthcare space and holds significant m
Biomerica, Inc. has announced the appointment of Jack Kenny to its Board of Directors, leveraging his extensive experience in the healthcare sector. With a notable history of driving success at Meridian Bioscience, Kenny aims to support the launch of Biomerica's inFoods IBS product. This innovative test aims to improve patient outcomes for individuals suffering from IBS by allowing targeted dietary recommendations. His presence on the board is anticipated to facilitate further growth and development within the company.
Read more →BMRABiomerica Reports Fiscal 2023 Year End Results
Biomerica, Inc. reported its fiscal 2023 financial results, revealing a revenue decrease to $5.3 million, primarily due to lower COVID test sales. Excluding these sales, revenue increased by 15% from the previous fiscal year. Noteworthy achievements include the successful pilot program launch for the inFoods IBS product and plans for a national rollout by Q1 2024. Biomerica has also patented its inFoods technology for various medical conditions, expanding its commercial viability.
Read more →BMRABiomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
Biomerica Inc. has received a Notice of Allowance for a patent in China regarding an AI-based system that predicts adverse food reactions based on individual medical data. This system is designed to enhance dietary safety by analyzing patients' health records to determine safe food ingredients. The technology also aims to recommend alternative food options to avoid harmful ingredients. This development is regarded as a significant advancement in personalized and preventive healthcare.
Read more →BMRABiomerica’s inFoods IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
Biomerica, Inc. has announced that its inFoods IBS test is now available through Gastro Health in Miami, providing a new treatment option for patients suffering from Irritable Bowel Syndrome (IBS). This personalized approach identifies specific foods that trigger symptoms in individual patients, allowing for focused dietary changes that may alleviate symptoms. Clinical studies have indicated that this method can lead to significant improvements in key IBS symptoms, presenting a safer alternative to conventional drug therapies. Biomerica aims for future expansion of this service to other Gastro Health offices to benefit a wider patient population.
Read more →BMRABiomerica Reports Q3 Fiscal 2023 Results
Biomerica, Inc. reported its fiscal third-quarter results, revealing a significant decline in revenues primarily due to the cessation of Covid-related product sales. However, the company noted a 16% increase in revenues from other products and completed validation testing for its inFoods IBS product. The absence of Covid test sales has led to a net loss of $5.3 million for the nine months ending February 28, 2023. Despite financial challenges, Biomerica remains optimistic, focusing on the launch of its innovative IBS diagnostic product, which aims to improve treatment for millions of patients.
Read more →BMRABiomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
Biomerica, Inc. has launched its InFoods IBS laboratory developed test (LDT) after completing validation testing. This test, performed in a CLIA-certified lab, aims to identify foods that trigger irritable bowel syndrome (IBS) symptoms in patients. Clinical trial data reveals that the treatment diet provided significant improvements in abdominal pain intensity compared to placebo, garnering interest from gastroenterologists. The InFoods IBS approach allows for targeted dietary recommendations rather than broad restrictions, potentially improving patient outcomes significantly.
Read more →BMRABiomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
Biomerica, Inc. announced the successful closing of a public offering of 3,333,333 shares of its common stock, raising $8 million in total gross proceeds. The shares were sold at a price of $2.40 per share, with the proceeds earmarked for general corporate purposes including clinical studies and product development. Craig-Hallum Capital Group LLC served as the sole managing underwriter for the offering, which follows previously filed registration statements with the SEC. The move indicates Biomerica's commitment to advancing its biomedical technology capabilities.
Read more →BMRA▼ -19.1%on this newsshared move
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
Biomerica, Inc. has announced the pricing of a public offering of 3,333,333 shares of its common stock at $2.40 per share, expected to raise approximately $8 million before expenses. The underwriter for this offering is Craig-Hallum Capital Group. Proceeds from the offering will be utilized for general corporate purposes, including conducting clinical studies and expanding marketing activities. The anticipated closing date for the offering is March 7, 2023, pending normal closing conditions.
Read more →BMRABiomerica Announces Proposed Underwritten Public Offering of Common Stock
Biomerica, Inc. has announced a proposed underwritten public offering of its common stock to support its corporate initiatives. The offering will utilize proceeds for clinical studies, marketing efforts, product research and development, and general working capital needs. However, market conditions may affect the timing and terms of the offering, which remains uncertain. Craig-Hallum Capital Group LLC is the sole managing underwriter for this offering.
Read more →BMRABiomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022
Biomerica, Inc. reported its financial results for the second quarter of fiscal 2023, noting significant challenges with a decrease in net sales to $1.5 million due to reduced demand for Covid-19 tests. However, the company highlighted the upcoming launch of its InFoods® IBS lab-developed test, expected to generate initial revenues in fiscal Q3. Additionally, the InFoods® treatment diet was recognized for its potential effectiveness in improving IBS symptoms, providing optimism amidst financial setbacks.
Read more →BMRABiomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
Biomerica, Inc. has appointed Dr. Brian E. Lacy, a renowned gastroenterologist from the Mayo Clinic, to its Scientific Advisory Board. Dr. Lacy will advise on the commercialization of Biomerica's InFoods® Technology, starting with the InFoods® IBS product, a diagnostic-guided therapy for managing Irritable Bowel Syndrome (IBS) symptoms. This new approach aims to identify specific foods that impact individual IBS symptoms and is designed to improve treatment options without drug side effects. The company is preparing for the nationwide launch and seeks to expand its clinical development efforts.
Read more →BMRABiomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect
Read more →BMRABiomerica InFoods IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting The Presented Clinical Study Data Showed InFoods® IBS Provided Significant Improvement in Several IBS Symptoms Including Abdominal Pain
Read more →BMRABiomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods® Technology Notice of Patent Allowance in Japan containing broad claims pertaining to treating Depression using the InFoods® Technology IRVINE, Calif., Oct. 13, 202
Read more →BMRABiomerica’s Aware Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
Aware® is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast. EZ Detect™ is a simple 2-minute, at-home test which detects an early warning sign of colorectal cancer
Read more →BMRABiomerica Plans Launch of InFoods IBS Test; Names Robert Carlson as Chief Commercial Officer
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022 Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development Executive IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasda
Read more →BMRABiomerica Reports Fiscal 2022 Year End Results
Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fisc
Read more →BMRABiomerica to Participate at BTIG Biotech Conference
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company’
Read more →BMRABiomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen, meaning that it is a known
Read more →BMRABiomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Biome
Read more →BMRABiomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant improvement in multiple symptom related endpoints including Abdominal Pain Intensity (
Read more →BMRABiomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods IBS Treatment for Patients with Irritable Bowel Syndrome InFoods IBS Diagnostic-Guided Therapy is the first therapy of its kind
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods IBS Treatment for Patients with Irritable Bowel Syndrome InFoods IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient spe
Read more →BMRA▼ -7.6%on this news
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter InFoods® IBS endpoint trial is complete, t
Read more →BMRABiomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million - InFoods IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be An
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million - InFoods IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. Irvine, California December 16,
Read more →BMRA▲ +6.7%on this news
Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening
Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at Houston Scientific Advisory Board to guide on programs to screen and test patients in US and other countries where colorectal cancer screening is limited due to cost
Read more →BMRABiomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today announced that the Canadian Patent Office has issued a notic
Read more →BMRABiomerica Launches New Website for Its Aware Breast Exam Device
Simple at-home breast exam device provides results within minutes Studies show increase in Breast Exam Sensitivity IRVINE, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness
Read more →BMRABiomerica Reports Results for Fiscal First Quarter ended August 31, 2021
Revenues up 10% over fiscal first quarter 2021, and 20% over fiscal fourth quarter 2021 Customer orders backlog of over $1.5 million at August 31, 2021 Following close of first fiscal quarter 2022, Walmart began online sales of Biomerica’s EZ Detect™ Colorectal Screening Test,
Read more →BMRABiomerica expects Completion of Patient Enrollment for its InFoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end. The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for treating all forms of IBS. InFoods® IBS product addresses the over $30 billion IB
Read more →BMRABiomerica Reports Fiscal 2021 Year End Results
Revenues increase 7.6% for fiscal 2021 vs fiscal 2020. InFoods® IBS Endpoint Trial expected to be fully enrolled in less than 2 weeks. Biomerica receives multiple notices of allowance for patents covering the InFoods® Technology Platform providing patent protection through 2036
Read more →BMRABiomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has issued a notice of allowance for Biomerica’s first patent pertaining to a revolutio
Read more →BMRA▲ +8.5%on this news
Biomerica Launches New Website For Its EZ Detect™ Colorectal Disease Screening Test
Digital Health Advertising and Social Media Campaigns launching alongside new site Currently in discussion with major retailers to increase distribution of EZ Detect™ Colon Disease Test IRVINE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announ
Read more →BMRANEWS Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori ( H. pylori ) Test, hp+detect - Prevalence of H. Pylori infection in the United States is approximately 35%
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect - Prevalence of H. Pylori infection in the United States is approximately 35% to 40% of the population IRVINE, CA--(June 24, 2021) - Biomerica
Read more →BMRABiomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian p
Read more →BMRABiomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients) Broadens InFoods® global patent coverage with recently allowed patents in Korea and Japan IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE
Read more →BMRABiomerica to Participate in Upcoming Investor Conferences
IRVINE, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced that it will be participating in two upcoming investor conferences: the Truist Life Sciences Series and LD Micro Invitational XI event
Read more →BMRABiomerica’s Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab
Less invasive nasal swab taken from front opening of the nose is more comfortable for patients Test can be performed by doctors, school and company nurses, and medical assistants, in any location without specialized equipment IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Bio
Read more →BMRABiomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including the first Japanese patent InFoods® IBS diagnostic-guided therapy clinical trial
Read more →BMRABiomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update
Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 FDA actively reviewing Company’s EUA submission for its first of its kind “at-home” Blood Collection kit used with the Biomerica COVID-19 IgG
Read more →BMRABiomerica S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark - Biomerica receives first orders and plans to ship tests in coming weeks - Clinical studies demonstrated an overall performance of 94
Biomerica S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark - Biomerica receives first orders and plans to ship tests in coming weeks - Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative ag
Read more →BMRABiomerica's InFoods Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment
Patient enrollment completion anticipated by the end of April 2021 InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatment Therapy seeks to identify patient-specific foods that trigger IBS symptoms and suffering Approximately 45 milli
Read more →BMRABiomerica Reports Fiscal 2021 1st Quarter Financial Results
IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020. Net sales for the three months ended August 31, 2020 were $1.14 millio
Read more →BMRABiomerica Reports Fiscal Year End May 31, 2020 Financial Results
Fiscal fourth quarter revenues increase 133.7% over the prior year Fiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced me
Read more →BMRABiomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors. IRVINE, CA - (
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors. IRVINE, CA - (August 31, 2020) - Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company s Chief Fin
Read more →BMRABiomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that off
Read more →BMRABiomerica Announces Filing of New Three Year Shelf Registration Statement
IRVINE, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (“SEC”) to replace its previous three year shelf r
Read more →BMRAThe University of Texas Health Science Center at Houston joins Biomerica s InFoods Irritable Bowel Syndrome ( " IBS " ) D iagnostic - G uided T herapy ( DGT ) clinical trial. - InFoods Diagnostic - Guided Therapy is d es
The University of Texas Health Science Center at Houston joins Biomerica s InFoods Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy ( DGT ) clinical trial. InFoods Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet
Read more →BMRABiomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19 - This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary b
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19 - This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. - This tes
Read more →BMRAMayo Clinic joins Biomerica s InFoods Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial. - Biomerica also announces its first Japanese patent has been granted for its InFoods IBS Diagnostic Guided
Mayo Clinic joins Biomerica s InFoods Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial. - Biomerica also announces its first Japanese patent has been granted for its InFoods IBS Diagnostic Guided Therapy technology - InFoods Diagnostic-Guided Therapy is
Read more →BMRABiomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution o New h igh -v olume production test allows Biomerica to expand i nternational distrib
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus
Read more →BMRABiomerica Announces Third Quarter Financial Results
IRVINE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the period ended February 28, 2019. Sales for the three months ending February 29, 20
Read more →BMRABiomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs - Price point of this high-
Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs - Price point of this high-volume laboratory version test is expected be as low as $10
Read more →BMRABiomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure - 10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airpo
Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure - 10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor s office - Biomerica has begun
Read more →BMRABiomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund February 26, 2020 16:41 ET | Source: Biomerica, Inc. IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the Company or Biomerica ) announced today that the Company com
Read more →BMRABiomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter
IRVINE, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the same period in the previous year, an increase of 6.4%. Net sales were $2,790,823 f
Read more →BMRABiomerica Reports 1st Quarter Fiscal 2020 Financials
IRVINE, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 for the same period in the previous year. Net loss for the three months ended August 31, 20
Read more →BMRABiomerica Announces Fiscal Year End 2019 Financial Results
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682 versus net sales of $5,564,185 in fiscal 2018. Net loss was $2,393,060 for fiscal 20
Read more →BMRABiomerica signs exclusive distribution agreement in China for its colorectal screening test with total minimum purchase requirement of $17 million over 7 years and an upfront pre-payment of $1 million.
IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase r
Read more →BMRABiomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products
Read more →BMRABiomerica Announces Updates for H. Pylori Clinical Studies
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. Based on recent discussions between Biomerica and the United States Food and Drug
Read more →BMRABiomerica Announces Second Quarter Financial Results
IRVINE, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the same period in the previous year. Net sales were $2,773,661 for the six months end
Read more →BMRABiomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo Score) in UC patients. The study highlights that Biomerica’s platform technology can
Read more →BMRABiomerica Reports 1st Quarter Fiscal 2019 Financials
Irvine, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,272,870 for the three months ending August 31, 2018, compared to $1,444,483 for the same period in the previous year. Net loss for the three months ended August 31, 20
Read more →BMRABiomerica Announces Fiscal Year End 2018 Financial Results
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185 versus net sales of $5,791,670 in fiscal 2017. Net loss was $1,465,828 for fiscal
Read more →BMRABiomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity
Read more →BMRABiomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms Approximately 45 million Americans suffer from IBS1 Studies being conducted at Beth Israel Deaconess Medical Center Inc., a Harvard Medi
Read more →BMRABiomerica adds Harry Leider, MD, MBA to Strategic Advisory Board
IRVINE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is chaired by Edward W. (Ned) Barnholt. Until recently, Dr. Leider served as Chief Medical Officer (C
Read more →BMRANEWS - For Immediate Release Mexico s COFEPRIS (Mexico s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer. -Biomerica ships first order to
NEWS - For Immediate Release Mexico s COFEPRIS (Mexico s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer. -Biomerica ships first order to Mexico- Irvine, California March 8, 2018 -- Biomerica, In
Read more →BMRABiomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
IRVINE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,613,636 for the three months ended November 30, 2017, compared to $1,432,206 for the same period in the previous year, an increase of 12.7%. Net sales were $3,058,119 f
Read more →BMRABiomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
- DGT Designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms - DGT can be used alongside current IBS drug treatments to potentially improve outcomes - Market research determined that 70 % of physicians surveyed would use DGT
Read more →BMRABiomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019
IRVINE, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that it has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea. Celtis has changed its name to Telcon Pharmaceuticals (“Telcon”). The License Agreement
Read more →BMRABiomerica Reports 1st Quarter Fiscal 2018 Financials
IRVINE, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,444,483 for the three months ending August 31, 2017, compared to $1,410,110 for the same period in the previous year, an increase of 2.4%. Net loss for the three months
Read more →BMRABiomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test
IRVINE, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that the Company has commenced clinical studies to evaluate the performance of its new and proprietary Helicobacter pylori (H. pylori) test. The clinical studies are being conducted a
Read more →BMRABiomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for the year
IRVINE, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA), a global provider of advanced diagnostic products, today reported net sales for the fiscal year 2017 were $5,791,670 versus net sales of $5,139,816 in fiscal 2016, an increase of 12.7% over the prior
Read more →BMRABiomerica Announces Point of Care Product Distribution Agreement with a Multinational Pharmaceutical Company
IRVINE, Calif. , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today a distribution agreement to supply one of its point of care products to a multinational pharmaceutical company for distribution in Mexico. This multinational pharmaceutical company g
Read more →BMRABiomerica to present at the 18th Annual B. Riley & Co. investor conference on May 24, 2017
IRVINE, CA--(Marketwired - May 23, 2017) - Biomerica Inc. (NASDAQ: BMRA) today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA. Zackary Irani, Chief Executive Officer of Biomerica, will presen
Read more →BMRABiomerica Announces Third Quarter Financial Results, Sales up 13.9% for Nine Months
IRVINE, CA--(Marketwired - April 17, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $4,342,247 for the nine months ending February 28, 2017, compared to $3,813,683 for the period ended February 29, 2016. Sales for the three months ending February 28, 2017 were
Read more →BMRABiomerica to present at the 29th Annual ROTH conference on March 13, 2017
IRVINE, CA--(Marketwired - March 09, 2017) - Biomerica Inc. (NASDAQ: BMRA) today announced it will present at the 29th Annual ROTH Conference being held March 12-15, 2017 in Dana Point, CA. Zackary Irani, Chief Executive Officer of Biomerica, will present a business update about
Read more →BMRABiomerica Announces Second Quarter Financial Results; Sales up Over 22% for the Quarter
IRVINE, CA--(Marketwired - January 18, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $1,432,206 for the three months ended November 30, 2016, compared to $1,165,080 for the same period in the previous year, an increase of 22.9%. Net sales were $2,842,317 for
Read more →BMRABiomerica Announces First Quarter Fiscal 2017 Financial Results, Sales Increase Over Prior Year
IRVINE, CA--(Marketwired - October 18, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today reported net sales of $1,410,110 for the three months ending August 31, 2016, compared to $1,286,993 for the same period in the previous year, a
Read more →BMRABiomerica Highlights Recent Scientific Reports Indicating Increased Prevalence of IBS
IRVINE, CA--(Marketwired - October 04, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today emphasized the market opportunity created by global market failure to effectively treat irritable bowel syndrome (IBS), further establishing the
Read more →BMRABiomerica to Present at 18th Annual Rodman & Renshaw Global Investment Conference
IRVINE, CA--(Marketwired - September 06, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today announced that Zackary Irani, Chief Executive Officer, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to
Read more →BMRABiomerica Announces Year End Results
IRVINE, CA--(Marketwired - August 30, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today reported net sales for the fiscal year 2016 were $5,139,816 versus net sales of $4,962,373 in fiscal 2015. Net loss before income taxes was $795,
Read more →BMRABiomerica Approved for Listing on the Nasdaq Capital Market
IRVINE, CA--(Marketwired - August 24, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "BMRA" on August 26, 2016. The Company
Read more →BMRABiomerica Updates Shareholders on Progress of Commercialization of Its New IBS Product
IRVINE, CA--(Marketwired - August 10, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that has issued an update on the progress of commercialization of its new IBS diagnostic guided therapy product. The update was filed as a form 8-k filing as a letter to shareholders and is
Read more →BMRABiomerica Forms Strategic Advisory Board and Expands Scientific Advisory Board
IRVINE, CA--(Marketwired - July 25, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that it added Edward W. (Ned) Barnholt to a newly formed Strategic Advisory Board and Dr. Anthony J. Lembo to its Scientific Advisory Board. Ned Barnholt is currently chairman of the KLA-Ten
Read more →BMRABiomerica Adds Dr. Mark Sirgo to Board of Directors
IRVINE, CA--(Marketwired - July 18, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that it has added Dr. Mark A. Sirgo to its Board of Directors, expanding the Board to six members which includes four outside members. Dr. Mark A. Sirgo served on the Board of Directors and
Read more →BMRABiomerica Signs Exclusive License Agreement for Korean Market With Total Value of up to $8.5 Million; Licensee Makes Equity Investment of $1m in Biomerica at $3 per Share
IRVINE, CA--(Marketwired - May 26, 2016) - Biomerica Inc. (OTCQB: BMRA) today announced that it has entered into an exclusive license agreement with Celtis Pharm Co. Ltd of South Korea granting Celtis an exclusive license to market and sell Biomerica's new InFoods® IBS (Irritable
Read more →BMRABiomerica Announces Third Quarter Financial Results, Sales up 10% for Nine Months
IRVINE, CA--(Marketwired - April 15, 2016) - Biomerica, Inc. (OTCQB: BMRA) today reported net sales of $3,813,683 for the nine months ending February 29, 2016, compared to $3,467,450 for the same period in the previous year. Sales for the three months ending February 29, 2016 wer
Read more →BMRABiomerica Announced That Its International Patent Application for IBS Was Reviewed by the ISA and All Claims Have Been Deemed Novel and Non-Obvious
IRVINE, CA--(Marketwired - March 14, 2016) - Biomerica Inc. (OTCBB: BMRA) announced that the International Search Authority (ISA) has deemed that all its International Patent Application claims for its composition and methods to identify trigger foods for Irritable Bowel Syndrome
Read more →BMRABiomerica to Present at the ROTH Conference on March 16, 2016
IRVINE, CA--(Marketwired - March 10, 2016) - Biomerica Inc. (OTCBB: BMRA) ) today announced that Zackary Irani, Chief Executive Officer of Biomerica, will present a business update about its IBS (Irritable Bowel Syndrome) product at the Roth Capital Partners 28th Annual Growth S
Read more →BMRABiomerica Announces Executive Advisor Appointment for Medical Affairs and Research
IRVINE, CA--(Marketwired - January 08, 2016) - Biomerica Inc. (OTCBB: BMRA) announced today the appointment of Charles A. Carter, PharmD, MBA, as a senior advisor with the main responsibilities of Executive Director of Medical Affairs and Research. He will work with the company's
Read more →BMRABiomerica Reports First Quarter Results; Sales Up Over 24%
IRVINE, CA--(Marketwired - October 16, 2015) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2015. Fiscal 2016 first
Read more →BMRABiomerica Working With FDA on Submission for Its IBS Product
IRVINE, CA--(Marketwired - Sep 29, 2015) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that following a meeting with FDA on September 17, 2015, Biomerica is moving forward with gui
Read more →BMRABiomerica Announces Conference Call Regarding Its Product and Recent Developments in the Irritable Bowel Syndrome (IBS) Market
IRVINE, CA--(Marketwired - Jul 6, 2015) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, will hold a conference call to discuss its product and recent developments in the Irritable Bowel Syndrome (IB
Read more →BMRABiomerica Announces Its First Brazilian ANVISA Approvals and a New Distribution Channel in Brazil
IRVINE, CA--(Marketwired - Jun 29, 2015) - Biomerica, Inc. (OTCBB: BMRA) today announced that it received its first Brazilian ANVISA approvals for several of its clinical lab products. ANVISA is Brazil's equivalent to the US FDA, and is responsible for the oversight of all pharma
Read more →BMRABiomerica Announces Third Quarter Financial Results and Establishes Scientific Advisory Board
IRVINE, CA--(Marketwired - Apr 15, 2015) - Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $3,467,450 for the nine months ending February 28, 2015, compared to $3,441,299 for the same period in the previous year. Sales for the three months ending February 28, 2015 were
Read more →BMRABiomerica Has Filed a First Set of Patent Applications With the USPTO for a New Test to Aid in the Treatment of a Gastrointestinal Disorder
IRVINE, CA--(Marketwired - Jan 14, 2015) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that it has filed a first set of patent applications with the U.S. Patent and Trademark Offic
Read more →BMRABiomerica Reports First Quarter Results
IRVINE, CA--(Marketwired - Oct 16, 2014) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2014. Fiscal 2015 first quar
Read more →BMRABiomerica to Supply Its Colorectal Screening Point of Care Test to Multinational Pharmaceutical Company With Over $40 Billion in Sales
IRVINE, CA--(Marketwired - Aug 11, 2014) - Biomerica, Inc. (OTCBB: BMRA) announced today it will supply its EZ Detect colorectal screening test to a multinational pharmaceutical company that has over $40 billion in revenues and over 70,000 employees worldwide. The EZ Detect produ
Read more →BMRABiomerica Announces Two New China CFDA Approvals and a New Distribution Channel in China
IRVINE, CA--(Marketwired - Jun 4, 2014) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that it received two new China CFDA approvals for its Parathyroid Hormone (PTH) and Calcitonin
Read more →BMRABiomerica Announces Completion of Strategic Investment
IRVINE, CA--(Marketwired - Jan 22, 2014) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported it has closed a strategic investment from its new China distribution partner. In total the new
Read more →BMRABiomerica to Supply Two of Its Point of Care Products to Multinational Pharmaceutical Company With Over $40 Billion in Sales
IRVINE, CA--(Marketwired - Jan 14, 2014) - Biomerica, Inc. (OTCBB: BMRA) announced today it will supply two of its point of care products to a multinational pharmaceutical company for distribution in one European country with the possibility of expanding into multiple other count
Read more →BMRABiomerica Announces Year End Results -- Sales Up Over 6%
IRVINE, CA--(Marketwired - Aug 30, 2013) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2013 were $6,472,960 versus net sales of $6,081,131 in fiscal 20
Read more →BMRABiomerica Receives Approval to Market Its H. Pylori and PTH Products in Mexico and Appoints New Distributor in Mexico
IRVINE, CA--(Marketwired - Aug 7, 2013) - Biomerica, Inc. (OTCBB: BMRA) announced today that it has received approval to market and sell its H. Pylori and Parathyroid Hormone (PTH) diagnostic tests in Mexico. The company also announced that it has appointed a new distributor in M
Read more →BMRABiomerica Reports First Quarter Revenue Growth of 20.9%, Net Income up Over 147%
IRVINE, CA--(Marketwire - Oct 15, 2012) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2012. Fiscal 2013 first quart
Read more →BMRABiomerica Announces Year End Results: Sales up Over 24%; Net Income $0.08 per Share Versus $0.02 per Share
IRVINE, CA--(Marketwire - Aug 30, 2012) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net income of $548,435, or $0.08 per share, for the fiscal year ended May 31, 2012, compared to
Read more →BMRABiomerica Introduces Two New E. coli Tests: Verotoxin and E. coli 0157
IRVINE, CA--(Marketwire - Mar 6, 2012) - Biomerica, Inc. (OTCBB: BMRA) announced today that it has introduced two new E. coli tests for detecting verotoxin and E. coli 0157. E. coli is an important cause of diarrheal disease outbreaks and is associated with serious medical compl
Read more →BMRABiomerica Launches New Patented Test to Identify Individuals at Risk of Developing Severe Side Effects From Thiopurine Drugs
IRVINE, CA--(Marketwire - Jan 31, 2012) - Biomerica, Inc. (OTCBB: BMRA) announced that it has launched a new patented Thiopurine methyltransferase (TPMT) test to detect patients who are at risk of developing severe or fatal side effects if treated with the class of thiopurine dru
Read more →BMRABiomerica Reports First Quarter Revenue Growth of 19.5%
IRVINE, CA--(Marketwire - Oct 18, 2011) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2011. Fiscal 2012 first quart
Read more →BMRABiomerica Awarded Grants Under the Qualifying Therapeutic Discovery Project Program
IRVINE, CA--(Marketwire - November 30, 2010) - Biomerica, Inc. (OTCBB: BMRA) today announced that the company has been awarded over $357,000 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The program was highly competitive with nearly seven thousand
Read more →BMRABiomerica Announces First Quarter Financial Results
IRVINE, CA--(Marketwire - October 18, 2010) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported diagnostic net sales of $1,177,712 for the first quarter of fiscal 2011 ended August 31, 20
Read more →BMRABiomerica Receives CE European Approval for New One of a Kind Simple Consumer Test to Determine Allergy to Dogs
IRVINE, CA--(Marketwire - August 23, 2010) - Biomerica, Inc. (OTCBB: BMRA) announced today that it has introduced a new 15 minute consumer home test to determine allergy to dogs. The Company has just received CE mark approval to market and sell the product directly to consumers t
Read more →BMRABiomerica Purchases Patented Technology and Manufacturing Rights for a New TPMT Test to Indentify Individuals at Risk of Developing Severe Side Effects From Thiopurine Drugs
IRVINE, CA--(Marketwire - June 8, 2010) - Biomerica, Inc. (OTCBB: BMRA) announced that it has purchased a patented technology and the manufacturing rights for a new Thiopurine methyltransferase (TPMT) test to detect patients who are at risk of developing severe side effects if tr
Read more →BMRABiomerica Purchases the Technology, Know-How and Manufacturing Rights for 7 New Gastrointestinal Enteric Tests
IRVINE, CA--(Marketwire - January 12, 2010) - Biomerica, Inc. (OTCBB: BMRA) announced that it has purchased the technology, know-how and manufacturing rights for seven new gastrointestinal enteric disease tests from an undisclosed Company. The seven new tests detect certain pa
Read more →BMRABiomerica Announces Plans for New Headquarters in Irvine, California
IRVINE, CA--(Marketwire - October 28, 2009) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced their move to a new Corporate, R&D and Manufacturing facility in Irvine, California. B
Read more →BMRABiomerica Purchases the Assets, Technology and Rights for New Celiac Disease Tests
NEWPORT BEACH, CA--(Marketwire - April 28, 2009) - Biomerica, Inc. (OTCBB: BMRA) announced that it has purchased the assets, technology and rights for three new Celiac disease tests from an undisclosed European Company. The three new products include a test to detect antibodie
Read more →BMRABiomerica Receives CE Mark Approval for 5-Minute Home Test for Kidney Disease Screening for Diabetic and Hypertensive Individuals
NEWPORT BEACH, CA--(Marketwire - April 21, 2009) - Biomerica, Inc. (OTCBB: BMRA) announced that it has received approval to CE mark its 5-minute home diagnostic test for detecting Microalbumin, micro amounts of albumin in urine. Albumin is normally found in the blood and filte
Read more →BMRABiomerica Announces Sale of Minority Interest in Lancer Orthodontics, Inc.
NEWPORT BEACH, CA--(Marketwire - May 29, 2008) - On May 27, 2008, Biomerica sold its investment in Lancer Orthodontics, Inc., in a private transaction. Net proceeds from the sale were $1,083,444. The investment was carried on the Biomerica balance sheet at date of sale at a va
Read more →BMRABiomerica Announces Record Year End Results
NEWPORT BEACH, CA--(Marketwire - August 30, 2007) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported stand-alone results of diagnostic net sales of $5,748,319 for the fiscal year 2007
Read more →BMRABiomerica Receives CE Mark Approval for 15-Minute Home Test for Ulcer Screening
NEWPORT BEACH, CA--(Marketwire - August 7, 2007) - Biomerica, Inc. (OTCBB: BMRA) announced that it received CE mark approval for its 15-minute home diagnostic test for detecting Helicobacter pylori (H. pylori), a bacterium responsible for over 85% of ulcers. The one step test
Read more →BMRABiomerica Board of Directors Adds New Member
NEWPORT BEACH, CA--(Marketwire - July 17, 2007) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that its board of directors has increased the size of the board from five to six me
Read more →BMRABiomerica Announces Income of $697,034 on Sale of Securities Held for Investment
NEWPORT BEACH, CA--(Marketwire - June 20, 2007) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announces income of $697,034 on the sale of the Hollister-Stier Laboratories securities it held for
Read more →BMRABiomerica Announces New Relationship With Commercial Bank of California and a New Line of Credit
NEWPORT BEACH, CA -- (MARKET WIRE) -- April 10, 2007 -- Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announces it has selected Commercial Bank of California for its principal banking relationshi
Read more →BMRANEWS FOR IMMEDIATE RELEASE --------------------- Contact: Zackary Irani 949-645-2111 BIOMERICA ANNOUNCES THIRD QUARTER FINANCIAL RESULTS O Diagnostic Revenues up over 19% for the 9 months ended O
biomerica_8kex99-1.txt --------------------- Contact: Zackary Irani BIOMERICA ANNOUNCES THIRD QUARTER FINANCIAL RESULTS O Diagnostic Revenues up over 19% for the 9 months ended O February 28, 2006 -- NEWPORT BEACH, Calif., April 14, 2005 - Biomerica, Inc. (OTC BB: BMRA) to
Read more →BMRAAMENDMENT of the Note, Loan and Modification Agreement This writing, effective as of
biomerica_8kex99-1.txt Note, Loan and Modification Agreement This writing, effective as of September 1, 2004, (the "Amendment"), modifies the terms of the Loan Agreement, dated September 12, 2000 (the "Loan Agreement") between Biomerica, Inc., a Delaware corporation (the "Bor
Read more →Competitive Position
How BMRA ranks across every disease it competes inCompetitive Position is a premium feature
See how BMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial